Nabel Elizabeth G
SEC-identified person · CIK 1619929 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Lyell Immunopharma, Inc. LYEL | Director | filed 2021–2026 |
| Moderna, Inc. MRNA | Director | filed 2018–2026 |
| Medtronic plc mdt | Director | filed 2015–2026 |
| Accolade, Inc. ACCD | Director | filed 2021–2025 |
| Abrdn Healthcare Opportunities Fund THQ | Director | filed 2018–2018 |
| Abrdn World Healthcare Fund THW | Director | filed 2018–2018 |
| Abrdn Healthcare Investors hqh | Director | filed 2018–2018 |
| Abrdn Life Sciences Investors HQL | Director | filed 2018–2018 |
| Medtronic INC mdt | Director | filed 2014–2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.